Antibiotics in acute exacerbations of chronic bronchitis

摘要: Acute exacerbations of chronic bronchitis (AECB) are a major contributor to morbidity and mortality in patients with obstructive pulmonary disease, accounting for more than 16 million physician office visits over 500,000 hospitalizations the USA each year. Antimicrobials have been recognized by clinical guidelines as an important component management AECB bacterial etiology. The challenge identifying most likely benefit from antimicrobial therapy is difficult setting. However, appropriate risk stratification patients, use antimicrobials within correct spectrum suitable duration, can improve outcomes while minimizing induction resistance. With improved design pharmacologic studies, differences be appreciated among various agents available treat AECB. Factors considered agent selection include local tissue penetration, effects on bacteriological eradication, duration therapy, speed resolution prevention or delay recurrences.